




The relative strengths and weaknesses of Lantern Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 7.9% points. The greatest weakness of Lantern Pharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 90% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	10,803
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,502
Liabilities, Non-Current	0
Other Assets	201
Other Compr. Net Income	-129
Other Expenses	0
Other Liabilities	0
Other Net Income	859
Other Revenues	0
Property and Equipment	32
Research and Development	11,514
Selling, General and Administrative Expense	6,464

Output Variable	Value in 1000 USD
Assets	11,036
Liabilities	4,502
Expenses	17,978
Revenues	0
Stockholders Equity	6,534
Net Income	-17,119
Comprehensive Net Income	-17,184
BaseVar	17,252
ECR before Limited Liability	-38%
Economic Capital Ratio	139%